Iota Pharma and Beactica announce new commercial alliance

The Iota-Beactica platform couples comprehensive, site-directed fragment-based drug discovery (FBDD) libraries to state-of-the-art fragment and lead screening using surface plasmon resonance (SPR) biosensor technology, enabling the rapid progression of new discovery programs from concept to optimized lead.

Based on rapid determination of ligand-target interaction information, and using a unique combination of fragment-based drug screening and medicinal chemistry-led design approaches, applicable to a wide range of new targets, the platform will initially focus on the development of new classes of kinase inhibitors. The reagents, tools and technologies developed by the two companies will be commercialized through drug discovery partnerships with pharmaceutical companies active in the kinase area.

Per Kallblad, CEO of Beactica, said: “We are delighted to work with Iota to expand our existing drug discovery platform. The combination of Iota’s proprietary FBDD engine with Beactica’s SPR screening technology will be an excellent way to pursue the discovery and optimization of new kinase inhibitors.”